Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orenitram in Pulmonary Arterial Hypertension (FREEDOM-C2)
NCT00887978Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2009
- Primary completion
- Jul 2011
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo with UT-15C SR (2 arms). Primary endpoint: 6-minute Walk Distance at 16 weeks. Started Jun 2009; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00887978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887978.